Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in
precision genetic medicine for rare diseases, today announced 21
recipients of Route 79, The Duchenne Scholarship Program. This is
the third year of the scholarship program, which was created to
recognize exceptional individuals with Duchenne muscular dystrophy
as they pursue their post-secondary education. Recipients were
chosen by an independent selection committee composed of Duchenne
community members, who consider each applicant’s community
involvement and a personal essay. Each student will receive a
scholarship of up to $5,000.
“It is our great privilege to announce and
congratulate the 2020 recipients of Route 79, The Duchenne
Scholarship Program. With each new class of applicants, we are
reminded of the varied interests, skills, and goals of these bright
young people. Their perseverance and resiliency, particularly in
the face of the challenges and uncertainties brought on by COVID,
set a powerful example for others living with Duchenne,” said Diane
Berry, Sarepta’s Senior Vice President of Global Health Policy,
Government and Patient Affairs. “It is an honor to play a role in
supporting their journey in higher education and we wish them great
success. Additionally, I want to extend gratitude and appreciation
to the selection committee for generously giving of their time to
review the applications and essays.”
2020 Named Recipients - Route 79, The
Duchenne Scholarship Program
Praise Akintola, Farmingdale State College
Porter Aydelotte, Saddleback College
Donovan Carlson, University of Illinois at
Urbana-Champaign
Tyler Cooley, Arizona State University
Lucas Currier, Great Bay Community College
Benjamin Dupree, The University of Texas at
Arlington
Cole Dutton, West Texas A&M University
Aiden Fecteau, Eastern Connecticut State
University
Yuvaraj Gambhir, University of Pennsylvania
Justin Gibbons, Saint Bonaventure University
William Hancock, Merrimack College
Joshua Jurack, James Madison University
Brian Le, Stanford University
Brian Madura, New Jersey Institute of
Technology
Alice McConnell, University of Idaho
Nicholas O'Neill, Morrisville State College
Spencer Poole, Saint Joseph’s College - Suffolk
Campus
Jordan Reidenberg, University of Delaware
Nathan Rothe, Texas Christian University
Christian Tumminello, Pennsylvania College of
Technology
Jack Willis, Syracuse University
Scholarship recipients are chosen by an
independent committee of Duchenne community members based on each
applicant’s essay and demonstrated level of community involvement.
Submissions are de-identified for the voting panel with no
indication of whether the candidate has received, or plans to
receive, a Sarepta therapy.
About Route 79, The Duchenne
Scholarship Program
Route 79, The Duchenne Scholarship Program
is designed to help students diagnosed with Duchenne muscular
dystrophy (Duchenne) pursue their post-high school educational
goals. There are 79 exons in the dystrophin gene impacted by
Duchenne, and the route traveled by every person with Duchenne is
distinct. Sarepta’s goal through this program is to acknowledge and
support individuals with Duchenne who are mapping out their future
via educational pursuits. Additional information is available at
https://www.sarepta.com/route79.
About Sarepta
TherapeuticsAt Sarepta, we are leading a revolution in
precision genetic medicine and every day is an opportunity to
change the lives of people living with rare disease. The Company
has built an impressive position in Duchenne muscular dystrophy
(DMD) and in gene therapies for limb-girdle muscular dystrophies
(LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth
(CMT), and other CNS-related disorders, with more than 40 programs
in various stages of development. The Company’s programs and
research focus span several therapeutic modalities, including RNA,
gene therapy and gene editing. For more information, please
visit www.sarepta.com or follow us
on Twitter, LinkedIn, Instagram and Facebook.
Internet Posting of
InformationWe routinely post information that may be
important to investors in the 'For Investors' section of our
website
at www.sarepta.com. We encourage investors and potential investors to
consult our website regularly for important information about
us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Investors: Ian Estepan, 617-274-4052, iestepan@sarepta.com
Media: Tracy Sorrentino, 617-301-8566,
tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024